Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 15, 2026, 1:52 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 505–528 of 1,050 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Cell Transfer Clear all

Conditions: Metastatic Melanoma, Skin Cancer
Interventions: Cyclophosphamide, Fludarabine, Tumor Infiltrating Lymphocytes, IL-15; Drug · Biological
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years to 66 Years
Enrollment: 3 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2014
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Ischemic Cardiomyopathy
Interventions: Intramyocardial Injection of stem cells via NOGA Mapping, Control, then Stem Cell Therapy; Device · Other
Lead sponsor: Texas Heart Institute; Other
Eligibility: 18 Years to 70 Years
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2009
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Carpal Tunnel Syndrome
Interventions: Fat Injection, Steroid Injection; Other · Drug
Lead sponsor: Columbia University; Other
Eligibility: 18 Years and older
Enrollment: 100 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016 – 2027
U.S. locations: 1
States / cities: New York, New York

Conditions: Acute Lymphoblastic Leukemia, Obesity
Interventions: Tirzepatide, Resistance Exercise, Lifestyle Counseling; Drug · Behavioral
Lead sponsor: St. Jude Children's Research Hospital; Other
Eligibility: 18 Years and older
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 1
States / cities: Memphis, Tennessee

Conditions: Diffuse Large B-Cell Lymphoma (DLBCL), Primary Mediastinal Large B-cell Lymphoma, Burkitt Lymphoma, Anaplastic Large-Cell Lymphoma, Gray Zone Lymphoma
Interventions: Etoposide, Rituximab, Prednisone, Cyclophosphamide, Vincristine, Doxorubicin, MRI, CT, Biopsy, PET scan, Laparotomy, Ondansetron, Prochlorperazine, Omeprazole, Docusate Sodium + Sennosides, Lactulose; Drug · Biological · Diagnostic Test + 2 more
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 12 Years and older
Enrollment: 348 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1993 – 2024
U.S. locations: 5
States / cities: Fort Lauderdale, Florida • Baltimore, Maryland • Bethesda, Maryland + 2 more

Conditions: Ganglioneuroblastoma, Nodular, Neuroblastoma
Interventions: Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy, Carboplatin, Cisplatin, Computed Tomography, Cyclophosphamide, Dinutuximab, Doxorubicin, Echocardiography Test, Etoposide, FDG-Positron Emission Tomography and Computed Tomography Scan, Hematopoietic Cell Transplantation, Irinotecan, Isotretinoin, Leukapheresis, Magnetic Resonance Imaging, Melphalan, Multigated Acquisition Scan, Radiation Therapy, Radionuclide Imaging, Survey Administration, Temozolomide, Thiotepa, Topotecan, Tumor Resection, Vincristine; Procedure · Drug · Biological + 2 more
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: Up to 30 Years
Enrollment: 478 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2029
U.S. locations: 158
States / cities: Birmingham, Alabama • Mobile, Alabama • Mesa, Arizona + 127 more

Conditions: Graft vs Host Disease, Multiple Myeloma
Interventions: Myeloma Immunoglobulin Idiotype Vaccine-KLH, GM-CSF; Drug
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years to 60 Years
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1996 – 2005
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Benign Prostatic Hyperplasia, Lower Urinary Tract Symptom
Interventions: Rezum System, Rigid Cystoscopy; Device · Procedure
Lead sponsor: Boston Scientific Corporation; Industry
Eligibility: 50 Years and older · Male only
Enrollment: 197 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2016
U.S. locations: 15
States / cities: Tucson, Arizona • Denver, Colorado • Aventura, Florida + 12 more

Conditions: Melanoma, Unresectable (Stage III) Melanoma, Metastatic (Stage IV) Melanoma
Interventions: Omaveloxolone Capsules (2.5 mg/capsule), Ipilimumab (3 mg/kg), Nivolumab (240 mg), Omaveloxolone Capsules (10 mg/capsule), Omaveloxolone Capsules (50 mg/capsule); Drug
Lead sponsor: Biogen; Industry
Eligibility: 18 Years and older
Enrollment: 41 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2018
U.S. locations: 10
States / cities: Mobile, Alabama • Fayetteville, Arkansas • Aurora, Colorado + 7 more

Conditions: Lung Cancer
Interventions: Smoking cessation intervention, Counseling intervention, Nicotine patch; Behavioral · Other · Drug
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 21 Years to 65 Years
Enrollment: 462 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2002 – 2016
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Sickle Cell Disease
Interventions: Adherence Treatment Program, Education only; Behavioral
Lead sponsor: Johns Hopkins All Children's Hospital; Other
Eligibility: 13 Years and older
Enrollment: 16 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2022
U.S. locations: 1
States / cities: St. Petersburg, Florida

Conditions: Hodgkin Lymphoma, Non-Hodgkin Lymphoma, Plasma Cell Myeloma, Lymphoid Leukemia, Myeloid Leukemia, Myelodysplastic Syndromes, Multiple Myeloma
Interventions: Behavioral techniques; Behavioral
Lead sponsor: University of Wisconsin, Madison; Other
Eligibility: 18 Years to 74 Years
Enrollment: 39 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2018
U.S. locations: 1
States / cities: Madison, Wisconsin

Conditions: Anemia, Red Blood Cell Transfusion, Fatigability, Fatigue, Physical Function
Interventions: Red blood cell transfusion; Other
Lead sponsor: University of Chicago; Other
Eligibility: 18 Years and older
Enrollment: 23 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2025
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Chronic Graft Versus Host Disease, Hematologic and Lymphocytic Disorder, Steroid Refractory Graft Versus Host Disease
Interventions: Biopsy, Biospecimen Collection, Chimeric Antigen Receptor T-Cell Therapy, Computed Tomography, Echocardiography, Electronic Health Record Review, Leukapheresis, Lumbar Puncture, Magnetic Resonance Imaging, Quality-of-Life Assessment, Tafasitamab, X-Ray Imaging; Procedure · Biological · Other
Lead sponsor: City of Hope Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 27 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2028
U.S. locations: 1
States / cities: Duarte, California

Conditions: Hypoplastic Left Heart Syndrome
Interventions: c-kit+ cells; Biological
Lead sponsor: Joshua M Hare; Other
Eligibility: 1 Day to 21 Days
Enrollment: 25 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2024
U.S. locations: 4
States / cities: Atlanta, Georgia • Chicago, Illinois • Baltimore, Maryland + 1 more

Conditions: HNSCC, Melanoma, Gynecologic Cancer, Colorectal Cancer, Lung Cancer, Urogenital Cancer
Interventions: DP CD8 TIL, DP CD8 TIL KD, Low dose IL-2; Biological
Lead sponsor: AgonOx, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 18 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2026
U.S. locations: 1
States / cities: Portland, Oregon

Conditions: Chronic Ischemic Left Ventricular Dysfunction, Myocardial Infarction
Interventions: Autologous hMSCs, Autologous Human C-Kit CSCs II, Placebo, Biosense Webster MyoStar NOGA Injection Catheter System; Drug · Device
Lead sponsor: Joshua M Hare; Other
Eligibility: 21 Years to 89 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2032
U.S. locations: 1
States / cities: Miami, Florida

Conditions: Hidradenitis Suppurativa
Interventions: Brodalumab; Drug
Lead sponsor: Florida Academic Dermatology Centers; Other
Eligibility: 18 Years and older
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2020
U.S. locations: 1
States / cities: Coral Gables, Florida

Conditions: Skin Cancer
Interventions: Spectral Diagnosis Probe; Device
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 350 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2018
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Non-Small Cell Lung Cancer
Interventions: cis-diamminedichloroplatinum; Drug
Lead sponsor: University of Vermont; Other
Eligibility: 18 Years and older
Enrollment: 6 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2025
U.S. locations: 1
States / cities: Burlington, Vermont

Conditions: Carcinoma, Non Small Cell Lung (NSCLC)
Interventions: Carboplatin, Paclitaxel, Daily hyperfractionated radiation therapy; Drug · Radiation
Lead sponsor: Duke University; Other
Eligibility: 18 Years and older
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2021
U.S. locations: 1
States / cities: Durham, North Carolina

Conditions: Chronic Graft Versus Host Disease
Interventions: ECP Methoxsalen, Standard of Care; Drug
Lead sponsor: Mallinckrodt; Industry
Eligibility: 18 Years to 99 Years
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2015
U.S. locations: 11
States / cities: Miami, Florida • Indianapolis, Indiana • New Orleans, Louisiana + 7 more

Conditions: Phase 1, NK Cell, IL13Ra, EGFRvIII, Chimera Antigen Receptor (CAR), NR3C1, Recurrent Glioblastoma
Interventions: NK Cells; Drug
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 36 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2030
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Nonsmall Cell Lung Cancer Stage
Interventions: SBRT; Radiation
Lead sponsor: Georgetown University; Other
Eligibility: 18 Years and older
Enrollment: 35 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2033
U.S. locations: 1
States / cities: Washington D.C., District of Columbia

Search by objective public record fields.

Use of IL-15 After Chemotherapy and Lymphocyte Transfer in Metastatic Melanoma

Autologous Stem Cells for Cardiac Angiogenesis (FOCUS HF)

Lipografting Versus Steroid Injections for Treatment of Carpal Tunnel Syndrome

Resistance Exercise and Incretin Mimetic for Cardiometabolic Health in Survivors of ALL With Obesity

Dose-Adjusted EPOCH Chemotherapy and Rituximab (CD20+) in Previously Untreated Aggressive Non-Hodgkin's Lymphoma

Dinutuximab With Chemotherapy, Surgery and Stem Cell Transplantation for the Treatment of Children With Newly Diagnosed High Risk Neuroblastoma

Active Immunization of Sibling Bone Marrow Transplant Donors Against Purified Myeloma Protein of the Recipient Undergoing Allogeneic Bone Marrow Transplantation

Safety and Efficacy Study for the Treatment of BPH (Enlarged Prostate)

RTA 408 Capsules in Patients With Melanoma - REVEAL

Computer-Assisted Counseling in Helping African American Smokers Stop Smoking

Pilot Evaluation of a Motivational Interviewing Intervention Targeting Adherence Behaviors in Youth With Sickle Cell Disease

Biobehavioral Intervention to Enhance Hematopoietic Stem Cell Transplant Recovery

A Trial to Assess the Effect of Transfusion Strategies on Fatigability Levels After Hospital Discharge

Allogeneic CD6 Chimeric Antigen Receptor T Regulatory Cells (CD6-CAR Tregs) for the Treatment of Patients With Chronic Graft Versus Host Disease After Allogeneic Hematopoietic Cell Transplantation

The CHILD Trial: Hypoplastic Left Heart Syndrome Study.

Adoptive Cell Therapy Using Cancer Specific CD8+ Tumor Infiltrating Lymphocytes in Adult Patients With Solid Tumors

The Transendocardial Autologous Cells (hMSC) or (hMSC) and (hCSC) in Ischemic Heart Failure Trial.

Treatment of Moderate Hidradenitis Suppurativa

Spectral Diagnosis of Cutaneous Malignancy

Intratumoral Cisplatin for Resectable NSCLC

Locally Advanced NSCLC Hyperfractionated RT

Extracorporeal Photopheresis (ECP) With Methoxsalen for Chronic Graft Versus Host Disease (cGVHD)

A Phase1 Clinical Trial Evaluating Locoregional Delivery Of Engineered NK Cells Containing IL13Ra And EGFvIII Chimeric Antigen Receptor (CAR), IL-21 Secretion And Deleted TGF-BetaR2 And NR3C1 In Recurrent Glioblastoma

SBRT for Ultra-Central NonSmall Cell Lung Cancer